These challenges are common (35, 36); for example, a study on the therapeutic mAb daratumumab found that the mAb saturates the myeloma cell marker CD38 and interferes with the diagnostic CD38 antibodies (37). This evidence concerns the gene CD38 and plasma cell myeloma.